MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

(2013) F Zagouri et al.   BRITISH JOURNAL OF CANCER

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

(2012) K. P. Raghav et al.   CLINICAL CANCER RESEARCH

Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer

(2012) S Gastaldi et al.   ONCOGENE

ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells

(2011) Xuefeng Liu et al.   AMERICAN JOURNAL OF PATHOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

(2010) Yoon-La Choi et al.   BMC CANCER

Use of standard markers and incorporation of molecular markers into breast cancer therapy

(2010) Manfred Kaufmann et al.   CANCER

MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor-Dependent Fashion to Suppress Carcinoma Growth

(2010) Y.-W. Zhang et al.   CANCER RESEARCH

Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells

(2010) F. Hochgrafe et al.   CANCER RESEARCH

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

(2009) S Agarwal et al.   BRITISH JOURNAL OF CANCER

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer

(2009) C. R. Graveel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

(2009) M. G. Ponzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells

(2008) K. L. Mueller et al.   CANCER RESEARCH

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

(2008) D. L. Shattuck et al.   CANCER RESEARCH

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY